BioCatalystWatch
FHTXWorkspace / FHTX / OverviewCompany library
Foghorn Therapeutics Inc. logo

Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc. (FHTX)

Website

Featured programme · ARID1B

Price
Market cap
Next catalyst—
Cash

Chart & Events

Candle interval

Core Clinical

Selective EP300 degrader

EP300

Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

Selective EP300 degrader

EP300

Upcoming / outlook

Other pipelines

FHT-171

CBP

PreINDP1P2P3FilingApproved
Novel oral I&I program

Upcoming / outlook

  • Timing and evidence

ARID1B

ARID1B

PreINDP1P2P3FilingApproved
FHT-654

ARID1B

PreINDP1P2P3FilingApproved
FHT-273

EP300

PreINDP1P2P3FilingApproved

History / paused

SMARCA2 (BRM)

SMARCA4 (BRG1) × SMARCA2 (BRM)

PreINDP1P2P3FilingApproved

SMARCA4 (BRG1) × SMARCA2 (BRM)

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

FHTX PR & News

PR & News

FHTX SEC archive